Literature DB >> 12627047

The effects of stressful life events, coping, and cortisol on HIV infection.

Jane Leserman1.   

Abstract

What is the role of stress and coping in changes in immunologic and clinical indicators of human immunodeficiency virus disease progression? There is substantial evidence that stressful life events and passive coping strategies, such as denial, may have a detrimental effect on HIV disease progression. Given the harmful effects of stress and passive coping, the author reviews the limited research testing the efficacy of interventions, such as cognitive-behavioral therapies for HIV-infected persons. Finally, in trying to understand psychoimmune relationships in HIV, the evidence is examined for the mediating and direct effects of cortisol, a hormone associated with stress, on HIV disease progression. Delineating the role of psychosocial factors and cortisol on HIV disease progression may aid in the development of new interventions for this devastating disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627047     DOI: 10.1017/s1092852900023439

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  14 in total

1.  Change in urinary cortisol excretion mediates the effect of angry/hostile mood on 9 month diastolic blood pressure in HIV+ adults.

Authors:  Roger C McIntosh; Michael Antoni; Adam Carrico; Ron Duran; Barry E Hurwitz; Gail Ironson; Mary Ann Fletcher; Nancy Klimas; Mahendra Kumar; Neil Schneiderman
Journal:  J Behav Med       Date:  2017-02-02

2.  Stress buffering effects of oxytocin on HIV status in low-income ethnic minority women.

Authors:  Erin M Fekete; Michael H Antoni; Corina Lopez; Armando J Mendez; Angela Szeto; Mary Ann Fletcher; Nancy Klimas; Mahendra Kumar; Neil Schneiderman
Journal:  Psychoneuroendocrinology       Date:  2011-01-06       Impact factor: 4.905

3.  The unique challenges facing HIV-positive patients who smoke cigarettes: HIV viremia, ART adherence, engagement in HIV care, and concurrent substance use.

Authors:  Conall O'Cleirigh; Sarah E Valentine; Megan Pinkston; Debra Herman; C Andres Bedoya; Janna R Gordon; Steven A Safren
Journal:  AIDS Behav       Date:  2015-01

4.  The interaction of mindful-based attention and awareness and disengagement coping with HIV/AIDS-related stigma in regard to concurrent anxiety and depressive symptoms among adults with HIV/AIDS.

Authors:  Adam Gonzalez; Sondra E Solomon; Michael J Zvolensky; Carol T Miller
Journal:  J Health Psychol       Date:  2009-04

5.  Prefrontal cortical volume loss is associated with stress-related deficits in verbal learning and memory in HIV-infected women.

Authors:  Leah H Rubin; Vanessa J Meyer; Rhoda J Conant; Erin E Sundermann; Minjie Wu; Kathleen M Weber; Mardge H Cohen; Deborah M Little; Pauline M Maki
Journal:  Neurobiol Dis       Date:  2015-09-25       Impact factor: 5.996

6.  Exploration of the relevance of anxiety sensitivity among adults living with HIV/AIDS for understanding anxiety vulnerability.

Authors:  Adam Gonzalez; Michael J Zvolensky; Sondra E Solomon; Carol T Miller
Journal:  J Health Psychol       Date:  2010-01

Review 7.  HIV, cognition and women.

Authors:  Pauline M Maki; Eileen Martin-Thormeyer
Journal:  Neuropsychol Rev       Date:  2009-05-09       Impact factor: 7.444

Review 8.  HIV and depression: 2008 review and update.

Authors:  Judith G Rabkin
Journal:  Curr HIV/AIDS Rep       Date:  2008-11       Impact factor: 5.071

9.  Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population.

Authors:  Bradley N Gaynes; Brian Wells Pence; Joseph J Eron; William C Miller
Journal:  Psychosom Med       Date:  2008-03-31       Impact factor: 4.312

10.  Effects of faith/assurance on cortisol levels are enhanced by a spiritual mantram intervention in adults with HIV: a randomized trial.

Authors:  Jill E Bormann; Kirstin Aschbacher; Julie L Wetherell; Scott Roesch; Laura Redwine
Journal:  J Psychosom Res       Date:  2008-12-20       Impact factor: 3.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.